Benjamin Kelmendi, MD
Assistant Professor of Psychiatry
Research & Publications
Biography
News
Coauthors
Selected Publications
- Mechanisms of therapeutic change after psychedelic treatment in OCDMaloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.
- Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratingsChing T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.
- Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMAWarner-Schmidt J, Stogniew M, Mandell B, Rowland R, Schmidt E, Kelmendi B. Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA. Frontiers In Neuroscience 2024, 18: 1353131. PMID: 38389788, PMCID: PMC10882719, DOI: 10.3389/fnins.2024.1353131.
- Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratingsChing T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.
- What Is in a Name? The Many Meanings of “Psychedelic”O'Donnell K, Roberts D, Ching T, Glick G, Goldway N, Gukasyan N, Hokansen J, Kelmendi B, Ross S, Yaden M, Pittenger C. What Is in a Name? The Many Meanings of “Psychedelic”. Psychedelic Medicine 2023, 1: 187-189. DOI: 10.1089/psymed.2023.0011.
- Frontopolar multifocal transcranial direct current stimulation reduces conditioned fear reactivity during extinction training: A pilot randomized controlled trialAdams T, Kelmendi B, George J, Forte J, Hubert T, Wild H, Rippey C, Pittenger C. Frontopolar multifocal transcranial direct current stimulation reduces conditioned fear reactivity during extinction training: A pilot randomized controlled trial. Neurobiology Of Learning And Memory 2023, 205: 107825. PMID: 37699439, PMCID: PMC10872945, DOI: 10.1016/j.nlm.2023.107825.
- Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trialChing T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.
- Pharmacological effects of methylone and MDMA in humansPoyatos L, Pérez-Mañá C, Hladun O, Núñez-Montero M, de la Rosa G, Martín S, Barriocanal A, Carabias L, Kelmendi B, Taoussi O, Busardò F, Fonseca F, Torrens M, Pichini S, Farré M, Papaseit E. Pharmacological effects of methylone and MDMA in humans. Frontiers In Pharmacology 2023, 14: 1122861. PMID: 36873994, PMCID: PMC9981643, DOI: 10.3389/fphar.2023.1122861.
- Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSDLewis C, Tafur J, Spencer S, Green J, Harrison C, Kelmendi B, Rabin D, Yehuda R, Yazar-Klosinski B, Cahn B. Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Frontiers In Psychiatry 2023, 14: 959590. PMID: 36815187, PMCID: PMC9939628, DOI: 10.3389/fpsyt.2023.959590.
- Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activityWarner-Schmidt J, Pittenger C, Stogniew M, Mandell B, Olmstead S, Kelmendi B. Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity. Frontiers In Psychiatry 2023, 13: 1041277. PMID: 36704743, PMCID: PMC9873307, DOI: 10.3389/fpsyt.2022.1041277.
- Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case reportKelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.
- Imagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case StudyMaloney G, Kelmendi B, Pittenger C. Imagery Rescripting (ImRs) as an Adjunctive Treatment to Exposure and Response Prevention (ERP)-Resistant Obsessive-Compulsive Disorder: A Case Study. Clinical Case Studies 2022, 22: 174-191. DOI: 10.1177/15346501221123797.
- Enhancing Trauma-Memories Reconsolidation With One-Time Ketamine InfusionDuek O, Yutong L, Kelmendi B, Amen S, Gordon C, Levy I, Harpaz-Rotem I. Enhancing Trauma-Memories Reconsolidation With One-Time Ketamine Infusion. Biological Psychiatry 2021, 89: s298. DOI: 10.1016/j.biopsych.2021.02.743.
- Augmenting the Treatment of PTSD with Ketamine—a ReviewDuek O, Kelmendi B, Pietrzak R, Harpaz-Rotem I. Augmenting the Treatment of PTSD with Ketamine—a Review. Current Treatment Options In Psychiatry 2019, 6: 143-153. DOI: 10.1007/s40501-019-00172-0.
- O40. PTSD Augmented Psychotherapy With Ketamine (KPE) - First ResultsDuek O, Levy I, Yutong L, Gordon C, Kelmendi B, Harpaz-Rotem I. O40. PTSD Augmented Psychotherapy With Ketamine (KPE) - First Results. Biological Psychiatry 2019, 85: s122. DOI: 10.1016/j.biopsych.2019.03.305.
- The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive DisorderAdams T, Kelmendi B, Brake C, Gruner P, Badour C, Pittenger C. The Role of Stress in the Pathogenesis and Maintenance of Obsessive-Compulsive Disorder. Chronic Stress 2018, 2: 2470547018758043. PMID: 29527593, PMCID: PMC5841259, DOI: 10.1177/2470547018758043.